Biomica Successfully Completes Phase I Trial Enrollment for Microbiome-Based Immuno-Oncology Drug
REHOVOT, Israel, Jan. 17, 2024 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), today announced that the final patient has been enrolled in its Phase I clinical trial.
- The final patient completes Phase I trial enrollment, evaluating safety and tolerability for Biomica's microbiome-based immuno-oncology drug, BMC128
REHOVOT, Israel, Jan. 17, 2024 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), today announced that the final patient has been enrolled in its Phase I clinical trial. - Bristol Myers Squibb's Opdivo® is the immune checkpoint inhibitor in the trial.
- Biomica remains on track with preliminary results, and the first data point readout is expected in H1 2024.
- Dr. Elran Haber, CEO of Biomica, stated: "We are pleased to complete the Phase 1 Proof of Concept study enrollment, marking a critical step forward in developing our groundbreaking BMC128.